Chronic rhinosinusitis is one of the most common chronic inflammatory conditions of the airways, affecting a substantial share of adults worldwide and imposing significant quality-of-life and economic burdens. It is defined by persistent inflammation of the mucosa lining the nose and paranasal sinuses, and it is classified into clinical phenotypes such as disease with or without nasal polyps under the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 criteria. Despite its prevalence, the immunological mechanisms driving the disease remain incompletely understood, and one intriguing line of investigation has focused on the unexpected role of taste receptors in airway defense.

The science behind that line of research is genuinely striking. In 2009, a landmark study showed that the motile cilia of human airway epithelial cells are chemosensory, meaning they can detect chemicals in their environment. T2R38, the receptor encoded by TAS2R38, recognizes acyl-homoserine lactones, which are quorum-sensing molecules that bacteria use to communicate and coordinate the formation of biofilms. When T2R38 binds these bacterial signals, it triggers a cascade that produces nitric oxide within the epithelial cells. Nitric oxide, in turn, stimulates the cilia to beat faster and directly harms bacteria, accelerating mucociliary clearance, the conveyor-belt mechanism that sweeps mucus and trapped microbes out of the airways. In other words, the same receptor that lets people perceive the bitterness of compounds such as those in cruciferous vegetables also functions as a microbial sentry in the nose.

This dual role has clinical consequences. Previous work has linked T2R38 receptor polymorphisms to susceptibility to upper respiratory infections and to chronic rhinosinusitis requiring surgery, and genotype has even been reported to predict surgical outcomes in certain disease subtypes. Other studies have examined T2R38 expression and function in diseased sinus tissue and nasal polyps. But a methodological question has hovered over this entire literature: if researchers biopsy one anatomical site, say the inferior turbinate, can they generalize the measured TAS2R38 expression to the rest of the sinonasal cavity? If expression varied substantially between the maxillary, ethmoid, frontal, and sphenoid sinuses, or between polypoid and non-polypoid tissue, then sampling location could silently bias results and make studies from different centers difficult to compare.

To settle the question, the Vietnamese team designed a prospective cross-sectional study embedded in routine endoscopic sinus surgery. They recruited 67 patients with chronic rhinosinusitis diagnosed according to the EPOS 2020 criteria and harvested mucosal specimens from up to six anatomical sites in each patient: the inferior turbinate, the maxillary sinus, the ethmoid sinus, the frontal sinus, the sphenoid sinus, and nasal polyps when present. They also collected 29 non-inflammatory septal specimens as controls. In total, 337 mucosal samples were collected, an unusually dense spatial sampling of a single patient population for this kind of molecular study.

The molecular measurements followed rigorous standards. Relative TAS2R38 messenger RNA expression was quantified by reverse transcription quantitative polymerase chain reaction, or RT-qPCR, performed in accordance with the MIQE guidelines, the internationally accepted quality framework for quantitative PCR experiments, and normalized to the housekeeping gene GAPDH. After strict quality control, which excluded 84 specimens because of cycle threshold values outside acceptable limits or minute fibrous tissue yields, 253 valid specimens from 55 patients remained for analysis. The final dataset included 52 inferior turbinate samples, 50 maxillary samples, 49 ethmoid samples, 44 polyp samples, 43 frontal samples, and 15 sphenoid samples.

The analytical approach was as important as the sampling design. Because multiple biopsies came from the same patient, the data points are statistically clustered, and treating them as independent would inflate false confidence. The researchers therefore used linear mixed-effects modeling with patient-specific random intercepts as their principal framework, a technique that explicitly separates variation between individuals from variation within individuals across anatomical sites. They supplemented this with sensitivity analyses and fold-difference calculations based on the standard 2 to the power of negative delta delta Cq method.

The results were unambiguous. Mean delta Cq values, a measure inversely related to gene expression, were remarkably comparable across subsites, ranging only from 2.06 to 2.81, and an exploratory analysis of variance found no significant differences among sites. In the principal mixed-effects model, anatomical sampling site showed no statistically significant association with TAS2R38 expression. Crucially, the variance decomposition told the deeper story: inter-individual biological variance substantially exceeded intra-individual spatial variation, with an intraclass correlation coefficient of 0.333, meaning roughly a third of the variance in expression was attributable to differences between patients rather than differences between locations within a patient. The robustness of the conclusion held across six sensitivity scenarios, including the exclusion of the small sphenoid subset and multivariable adjustments for age and sex.

One exploratory observation adds biological intrigue. Diseased mucosa demonstrated an approximately 2.48-fold upregulation of TAS2R38 relative to non-site-matched septal controls, hinting that the inflammatory environment of chronic rhinosinusitis may itself alter the expression of this chemosensory defense receptor. The authors characterize this comparison as exploratory, and the control tissue was not matched to the disease sites, so it should be interpreted with appropriate caution. Still, it aligns with a growing body of work suggesting that the bitter taste receptor system is dynamically involved in airway inflammation rather than being a static genetic fixture.

The practical implications reach well beyond the operating theater. For translational airway researchers, the study provides evidence that inferior turbinate biopsy, one of the simplest and most accessible sampling procedures in the nose, could serve as a pragmatic surrogate for investigating sinonasal chemosensory innate defense, sparing patients and researchers the complexity of multi-site sampling. For clinicians, the finding reinforces the idea that a patient’s individual biology, including their TAS2R38 genotype and expression profile, may matter more for disease susceptibility and treatment response than the specific anatomy involved. And for the broader field of innate immunity, it adds a methodological anchor to a rapidly evolving story about how the airways borrow the molecular machinery of taste to defend themselves against microbial invaders. As research into bitter receptor-based therapies for airway disease continues to gather momentum, knowing that one well-chosen biopsy can speak for the whole cavity removes a persistent source of uncertainty from the evidence base.

Subject of Research: TAS2R38 bitter taste receptor gene expression across sinonasal anatomical sites in chronic rhinosinusitis

Article Title: Anatomical sampling site is not associated with TAS2R38 gene expression in chronic rhinosinusitis: A cross-sectional RT-qPCR study

Article References: Cao, M. T., Luong, T. L. A., & Nguyen, X. N. (2026). Anatomical sampling site is not associated with TAS2R38 gene expression in chronic rhinosinusitis: A cross-sectional RT-qPCR study. Molecular Biology Reports, 53(1), Article 1659. https://doi.org/10.1007/s11033-026-12838-z

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12838-z

Keywords: TAS2R38, bitter taste receptor, chronic rhinosinusitis, nasal polyps, RT-qPCR, linear mixed-effects model, innate immunity, nitric oxide, mucociliary clearance, endoscopic sinus surgery, inferior turbinate, sinonasal mucosa

But a stubborn handful of receptors has resisted every attempt at de-orphanization. TAS2R19, TAS2R42, TAS2R45, and TAS2R60 remain orphans, receptors with no known activating compounds, and their biological roles have therefore remained shrouded in uncertainty. At the same time, even among receptors classified as functional, genetic variation has produced variants labeled nonfunctional, sometimes on the basis of just one or a few amino acid substitutions. Two famous examples are TAS2R9 and TAS2R38. In TAS2R9, an alanine at position 187 yields a functional receptor, while a valine at the same position renders it unresponsive to known agonists such as the antibiotic ofloxacin. TAS2R38 is even more celebrated: its PAV variant makes people exquisitely sensitive to the bitter compounds phenylthiocarbamide and propylthiouracil, whereas the AVI variant is classed as nonfunctional and defines the classic taster-non-taster divide in human populations. Whether such variants are truly dead or have simply shifted their ligand preferences to unknown chemicals has been impossible to determine from sequence alone.

A new study by Praveen Kumar and Maik Behrens, published in Current Research in Food Science, tackles this puzzle from an unexpected angle. Instead of hunting for missing agonists, the researchers asked a more fundamental question: do these orphan and supposedly nonfunctional receptors even reach the cell surface, the location where a receptor must reside to detect compounds outside the cell? A receptor that fails to fold properly, or that gets stuck in the endoplasmic reticulum during biosynthesis, can never respond to any ligand, no matter how thorough the screening. Conversely, a receptor that traffics efficiently to the plasma membrane is structurally intact and remains a plausible candidate for future ligand discovery. The answer to this question provides a powerful clue about functionality that does not require knowing a single agonist.

To measure cell surface localization, the team employed a clever tagging strategy developed recently in their laboratory. Each receptor was engineered to carry an 11-amino-acid HiBiT sequence, a small peptide tag appended to the amino-terminal end of an sst3 export tag derived from the rat somatostatin receptor subtype 3, which is itself crucial for routing receptors to the plasma membrane. The HiBiT tag binds with high affinity to a complementary protein fragment called LgBiT, and together the two fragments generate luminescence. Because some of the commercial detection reagents are membrane-impermeable, they can only reach HiBiT tags exposed on the outside of living cells, allowing researchers to quantify exactly how much of each receptor sits at the cell surface. A second, lytic detection reagent breaks the cells open and reveals the total receptor population, permitting calculation of the fraction that successfully completed trafficking. The entire workflow runs on a fluorometric imaging plate reader, making it suitable for high-throughput analysis.

The first test cases were the taster and non-taster variants of TAS2R9 and TAS2R38. Functional assays in HEK293T-Gα16gust44 cells confirmed the expected behavior: the TAS2R38-PAV variant responded to propylthiouracil and the TAS2R9-187A variant responded to ofloxacin, while their non-taster counterparts remained silent. Importantly, adding the HiBiT tag did not abolish function, although the tagged TAS2R38 showed a slightly reduced response, a caveat the authors note openly. When the researchers then measured cell surface abundance using the luminescence assay, both functional and nonfunctional variants proved to be present at the plasma membrane. The non-taster TAS2R38-AVI variant reached the cell surface at a reduced fraction, about 6 percent of its total pool compared with 17 percent for the PAV variant, and the TAS2R9-187V variant showed only a modest reduction relative to its functional partner. Immunocytochemical staining of living, non-permeabilized cells with an anti-HiBiT antibody independently confirmed these surface-localization patterns.

These results carry significant implications for how scientists interpret receptor polymorphisms. For TAS2R9-187V, the data suggest that no gross defect in folding or routing explains its apparent nonfunctionality. Position 187 sits in the upper part of the fifth transmembrane domain, a region that could plausibly contribute to agonist binding. The authors therefore propose that rather than being a lost receptor, this variant may simply respond to a different, perhaps smaller, agonist that has not yet been tested. The bulkier valine residue could sterically reshape the ligand-binding pocket or restrict the conformational movements of the transmembrane helices needed for receptor activation. Similarly, for TAS2R38-AVI, the demonstration of structural integrity at the cell surface supports earlier speculation that this variant may have evolved altered ligand specificity, possibly responding to unknown compounds in the pulp of the Antidesma bunius fruit, which produces a peculiar bitter taste in individuals carrying the AVI haplotype.

The four orphan receptors yielded equally revealing results. All four could be detected at the cell surface by luminescence assays, but their trafficking efficiencies differed dramatically. TAS2R19 stood out as the star performer: 83 percent of its total receptor pool reached the plasma membrane, a proportion exceeding even that of TAS2R14, the human bitter receptor with the largest number of known agonists. TAS2R60 was by far the most abundantly produced receptor subtype, and although only 9 percent of it reached the surface, the absolute quantity there surpassed all TAS2Rs except TAS2R19. In sharp contrast, TAS2R42 and TAS2R45 showed negligible surface signals in immunocytochemical staining, with cell surface fractions of just 3 and 6 percent respectively. TAS2R42 is synthesized reasonably well but trafficked poorly, suggesting retention in the endoplasmic reticulum, while TAS2R45 appears to be produced at very low levels overall, raising the possibility that it may functionally represent an expressed pseudogene.

The contrasting profiles of the four orphans allow the authors to draw nuanced conclusions about why these receptors have resisted de-orphanization. For TAS2R19 and TAS2R60, biosynthesis and cell surface routing in heterologous cells clearly do not explain the absence of known agonists. Both receptors are closely related to already de-orphaned receptors in mice: the mouse receptor Tas2r135, an ortholog of TAS2R60, has 11 identified bitter agonists, and TAS2R19 is highly homologous to TAS2R20, which has 10 known agonists. Problems with coupling to the calcium signaling cascade used in the assay system also seem unlikely, given that far more distantly related receptors, including one from cartilaginous fish, have been successfully screened in the same cellular platform. The most probable explanation for these two receptors is simply that the right bitter compounds have not yet been tested, pointing toward unexplored chemical territory.

That territory, the authors argue, is vast and seriously under-sampled. Most bitter agonist discovery has focused on synthetic compounds and molecules from flowering plants, while bitter substances from animals, mushrooms and other fungi, prokaryotic organisms, and plants belonging to older lineages of the plant kingdom have barely been investigated. Recent work identifying bitter compounds from mushrooms, such as those isolated from the bracket fungus Amaropostia stiptica, illustrates the kind of neglected sources that could harbor activators for the remaining orphans. Closing this knowledge gap, the study suggests, will require intensified bioprospecting efforts guided by the growing recognition that bitter taste receptors do far more than guard the tongue. They are expressed in the gut, airways, and other tissues, where they influence hormone secretion, glucose homeostasis, and possibly innate defense, making every de-orphanized receptor a potential target for nutrition and medicine.

The HiBiT-based localization assay itself may prove to be the study’s most lasting contribution. By providing a rapid, quantitative, high-throughput readout of receptor biosynthetic integrity that requires no knowledge of agonists, the method offers a rational triage tool for the bitter taste receptor field. Receptors that traffic well, like TAS2R19 and TAS2R60, become priority targets for expanded ligand screening, while those with severe trafficking defects, like TAS2R42 and TAS2R45, may need engineered chaperones, modified expression systems, or tissue-specific organoid models to reveal their secrets. As the authors note, genetically engineered organoids derived from taste tissue or the intestine could eventually provide more natural cellular environments for such studies, overcoming limitations of immortalized cell lines that express numerous receptors endogenously. For now, the message is clear: four orphan receptors and two supposedly dead receptor variants are very much alive at the cell surface, waiting for the right molecule to wake them.

Subject of Research: Cell surface localization of orphan and nonfunctional human bitter taste receptors

Article Title: Cell surface localization of receptors considered nonfunctional and orphan bitter taste receptors

Article References: Kumar, P., & Behrens, M. (2026). Cell surface localization of receptors considered nonfunctional and orphan bitter taste receptors. Current Research in Food Science, 13, Article 101551. https://doi.org/10.1016/j.crfs.2026.101551

Image Credits: AI Generated

DOI: 10.1016/j.crfs.2026.101551

Keywords: bitter taste receptors, TAS2R, orphan receptors, HiBiT tag, cell surface localization, G protein-coupled receptors, TAS2R38, TAS2R9, de-orphanization, taste perception, receptor trafficking, food science